Abstract
Congenital heart defects (CHD) arise in part due to inherited genetic variants that alter genes and noncoding regulatory elements in the human genome. These variants are thought to act during fetal development to influence the formation of different heart structures. However, identifying the genes, pathways, and cell types that mediate these effects has been challenging due to the immense diversity of cell types involved in heart development as well as the superimposed complexities of interpreting noncoding sequences. As such, understanding the molecular functions of both noncoding and coding variants remains paramount to our fundamental understanding of cardiac development and CHD. Here, we created a gene regulation map of the healthy human fetal heart across developmental time, and applied it to interpret the functions of variants associated with CHD and quantitative cardiac traits. We collected single-cell multiomic data from 734,000 single cells sampled from 41 fetal hearts spanning post-conception weeks 6 to 22, enabling the construction of gene regulation maps in 90 cardiac cell types and states, including rare populations of cardiac conduction cells. Through an unbiased analysis of all 90 cell types, we find that both rare coding variants associated with CHD and common noncoding variants associated with valve traits converge to affect valvular interstitial cells (VICs). VICs are enriched for high expression of known CHD genes previously identified through mapping of rare coding variants. Eight CHD genes, as well as other genes in similar molecular pathways, are linked to common noncoding variants associated with other valve diseases or traits via enhancers in VICs. In addition, certain common noncoding variants impact enhancers with activities highly specific to particular subanatomic structures in the heart, illuminating how such variants can impact specific aspects of heart structure and function. Together, these results implicate new enhancers, genes, and cell types in the genetic etiology of CHD, identify molecular convergence of common noncoding and rare coding variants on VICs, and suggest a more expansive view of the cell types instrumental in genetic risk for CHD, beyond the working cardiomyocyte. This regulatory map of the human fetal heart will provide a foundational resource for understanding cardiac development, interpreting genetic variants associated with heart disease, and discovering targets for cell-type specific therapies.
Competing Interest Statement
J.M.E. has received materials from 10x Genomics unrelated to this study.
Funding Statement
Funding for this project was provided by the Applebaum Foundation, Additional Ventures (to J.M.E. and W.G.), Stanford Maternal and Child Health Research Institute (to J.M.E.), the BASE Research Initiative at the Lucile Packard Childrens Hospital at Stanford University (to J.M.E.), and the National Institutes of Health (R24HD000836 to I.A.G.). In addition: J. M. Engreitz acknowledges support from the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease (NNF21SA0072102); the NIH/NHGRI Impact of Genomic Variation on Consortium (UM1HG011972); and NIH/NHLBI (R01HL159176) W. R. Goodyer acknowledges support from NIH (K08 Mentored Clinical Scientist Research Career Development Award - 1K08HL15378501). X. R. Ma acknowledges support from NIHGRI training grant (2T32HG000044-21) M. U. Sheth acknowledges the support of an NSF Graduate Research Fellowship (DGE-1656518) and a graduate fellowship award from Knight-Hennessy Scholars at Stanford University. The Laboratory for Developmental Biology was supported by NIH Award Number 5R24HD000836 (to I.A.G) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. W. Qiu and R. Andersson acknowledge support from the Novo Nordisk Foundation (NNF20OC0059796) and the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease (NNF21SA0072102). H. Y. Kang acknowledges support from NIH Training Grant 5T32GM087237 and NIH 5R35GM141861-04. D. Amgalan acknowledges support from AHA Postdoctoral Fellowship (821920 and 23POSTCHF1019753) and the Stanford Maternal and Child Health Research Institute (MCHRI) Postdoctoral Support. T. Quertermous acknowledges support from NIH grants R01HL171045, R01 HL134817, R01HL139478, R01HL156846, R01HL151535, R01HL158525, UM1 HG011972, and the Irwin Foundation. M. Rabinovitch was supported by NIH/NHLBI grant R01 HL152134 and NIH/NHGRI grant HG011972, the Dwight and Vera Dunlevie Chair in Pediatric Cardiology at Stanford University, and the Gordon and Betty Moore and the BASE Research Initiative at the Lucile Packard Childrens Hospital at Stanford University. X. Qiu acknowledges support from NIH/NHGRI R00HG012887 and NIH DP2HG014282. The research of M. Kosicki, A. Visel and L.A. Pennacchio was supported by National Institutes of Health (NIH) grants R01HL162304 and R01HG003988 (to A.V. and L.A.P.) and conducted at the E.O. Lawrence Berkeley National Laboratory under the US Department of Energy Contract DE-AC02-05CH11231, University of California. We thank the technical team at the Lawrence Berkeley National Laboratory for generating transgenic mouse embryos. A. Kundaje acknowledges support from the Impact of Genomic Variation on Function Consortium (U01HG012069). J. P. Pirruccello acknowledges support from NIH grant K08HL159346. M. Gu acknowledges support from Additional Ventures (1019125) and NIH/NHLBI (R01HL166283) S. Kany acknowledges support from the Deutsche Forschungsgemeinschaft (521832260) Arun Padmanabhan acknowledges support from NIH grant K08HL157700, the Michael Antonov Charitable Foundation, and the Frank. A. Campini Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB, SCRO, and APB Committees of the Leland Stanford Junior University gave ethical approval for this work. IRB committee of the University of Washington gave ethical approval for this work. IRB committee of Cercle Allocation Services, Inc., gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Data Availability
Processed, deidentified single-cell 10x Multiome data are available at https://www.synapse.org/Synapse:syn63997960 Raw data are access-controlled and are available via dbGaP in compliance with the study design and consent.
